
    
      This intermediate-size expanded access protocol plans to treat approximately 50 adult
      participants, male and female, with moderate to severe ARDS due to COVID-19 infection.
      Participants who are 18 years of age or older will be enrolled at multiple clinical sites
      across the United States.
    
  